Telix Pharmaceuticals (TLX) AI Stock Analysis

• Market Cap: AU$4.94B
• Dividend Yield: N/A
• Average Volume (3M): 1.36M
• Price to Earnings (P/E): 287.6
• Beta (1Y): 1.23
• Revenue Growth: 60.23%
• EPS Growth: -66.98%
• Country: AU
• Employees: 415
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.02
• Shares Outstanding: 338,721,340
• 10 Day Avg. Volume: 1,165,560
• 30 Day Avg. Volume: 1,362,129
• PEG Ratio: 0.20
• Price to Book (P/B): 14.35
• Price to Sales (P/S): 10.41
• P/FCF Ratio: 906.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$27.89
• Price Target Upside: 94.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): 0.09
• Revenue Forecast (FY): AU$1.23B

• Rating: 65 Neutral
• Price Target: AU$15.00 ▲(4.75% Upside)

Telix Pharmaceuticals Ltd. demonstrates strong financial performance and positive earnings call highlights, driving the score. However, technical indicators suggest bearish momentum, and the high P/E ratio raises valuation concerns. Cash flow management and external challenges also weigh on the score.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Telix's products, enhancing its market position and supporting long-term business sustainability.

Product Expansion

Product expansion into new markets strengthens Telix's competitive edge and diversifies revenue streams, contributing to long-term growth.

Cash Position

A strong cash position provides Telix with the financial flexibility to invest in R&D and strategic initiatives, supporting future growth and stability.

Negative Factors

SEC Inquiry

The SEC inquiry could lead to regulatory scrutiny, potentially affecting Telix's reputation and operational focus, impacting long-term business operations.

Gross Margin Pressure

Pressure on gross margins from third-party products may affect profitability, challenging Telix's ability to maintain cost efficiency over time.

Competitive Pricing

Competitive pricing pressures could erode market share and profitability, posing a risk to Telix's long-term revenue growth and market position.

Telix Pharmaceuticals Business Overview & Revenue Model

Company Description

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

How the Company Makes Money

Telix Pharmaceuticals generates revenue primarily through the sale of its radiopharmaceutical products and therapies, which are often sold to hospitals and clinics for cancer treatment. The company also engages in partnerships and collaborations with other pharmaceutical and biotechnology companies to co-develop products, which can provide additional funding and shared resources. Licensing agreements and clinical trial collaborations can contribute to revenue, particularly if Telix's products gain market approval and achieve commercial success. Furthermore, Telix may receive milestone payments associated with the achievement of specific regulatory or commercial objectives within these partnerships, enhancing its overall revenue model.

Telix Pharmaceuticals Financial Statement Overview

Summary

Telix Pharmaceuticals Ltd. shows strong revenue and profit growth with improved margins and operational efficiency. The balance sheet is stable, though leverage levels should be monitored. Cash flow management needs improvement to sustain operational cash generation.

Income Statement

Telix Pharmaceuticals Ltd. demonstrated strong revenue growth with a significant increase from $502.5M in 2023 to $783.2M in 2024, marking a 55.8% growth rate. The gross profit margin improved to 65.0%, showcasing efficient cost management. The net profit margin rose to 6.4%, reflecting enhanced profitability compared to previous years. The EBIT and EBITDA margins were healthy at 10.5% and 11.8%, respectively, indicating strong operational performance. Overall, the income statement reflects robust growth and improving profitability.

Balance Sheet

The company's financial position is solid with a debt-to-equity ratio of 1.02, suggesting a balanced approach to financing. The return on equity (ROE) improved to 8.8%, indicating better utilization of equity to generate profit. An equity ratio of 37.5% shows moderate reliance on equity financing. The balance sheet reflects a stable financial structure with steady equity growth, but there remains a slightly high leverage that could pose risks in volatile market conditions.

Cash Flow

Despite a lack of operating cash flow in the latest year, Telix Pharmaceuticals achieved a positive free cash flow of $9M, a decline from $13.1M in the previous year, indicating a need for better cash flow management. The absence of operating cash flow raises concerns regarding the sustainability of cash generation through operations. The free cash flow to net income ratio suggests limited conversion of profit into cash. Overall, cash flow management needs improvement to ensure long-term liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.19B	783.21M	502.55M	160.10M	7.60M	5.21M
Gross Profit	674.14M	509.68M	314.39M	29.34M	-29.77M	-16.88M
EBITDA	85.71M	92.55M	22.97M	-92.84M	-70.07M	-54.20M
Net Income	34.76M	49.92M	5.21M	-104.08M	-80.51M	-44.89M
Balance Sheet
Total Assets	1.19B	1.52B	398.30M	255.35M	109.81M	157.82M
Cash, Cash Equivalents and Short-Term Investments	207.16M	710.35M	123.24M	116.33M	22.04M	77.94M
Total Debt	418.25M	581.45M	17.45M	10.45M	2.54M	2.21M
Total Liabilities	768.01M	948.22M	249.39M	178.44M	106.17M	78.81M
Stockholders Equity	421.94M	568.21M	148.91M	80.01M	2.16M	79.02M
Cash Flow
Free Cash Flow	5.92M	9.00M	13.09M	-77.83M	-60.67M	1.64M
Operating Cash Flow	36.39M	43.03M	23.88M	-63.97M	-59.33M	1.96M
Investing Cash Flow	-497.38M	-135.17M	-25.49M	-17.00M	-2.73M	-1.09M
Financing Cash Flow	630.70M	638.92M	10.19M	174.96M	2.85M	34.12M

Telix Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.32
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TLX, the sentiment is Negative. The current price of 14.32 is below the 20-day moving average (MA) of 14.51, below the 50-day MA of 15.30, and below the 200-day MA of 21.07, indicating a bearish trend. The MACD of -0.20 indicates Negative momentum. The RSI at 42.83 is Neutral, neither overbought nor oversold. The STOCH value of 35.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TLX.

Telix Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEU	78 Outperform	$2.50B	17.20	54.79%	―	12.35%	26.73%
CUV	73 Outperform	AU$618.98M	17.07	15.90%	0.38%	7.76%	1.55%
TLX	65 Neutral	AU$4.94B	287.55	3.21%	―	60.23%	-66.98%
PTX	56 Neutral	AU$90.43M	-9.45	-49.72%	―	―	10.78%
MSB	55 Neutral	$3.50B	―	-18.95%	―	198.58%	3.97%
IMM	52 Neutral	AU$375.80M	―	-35.86%	―	―	-19.21%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Telix Pharmaceuticals Corporate Events

Telix Pharmaceuticals to Release Shares from Voluntary Escrow

Telix Pharmaceuticals announced the release of 45,584 ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of Lightpoint Medical and its SENSEI® radio-guided surgery business. This release of shares is a strategic move following the acquisition, potentially impacting Telix’s market positioning by enhancing its operational capabilities in the radio-guided surgery sector.

Telix Pharmaceuticals to Release Shares from Voluntary Escrow

Telix Pharmaceuticals announced the release of 1,649,037 ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of Lightpoint Medical’s SENSEI® radio-guided surgery business. This release, scheduled for November 3, 2025, marks a significant step in the integration of Lightpoint Medical’s technologies, potentially enhancing Telix’s market position in the field of minimally invasive and robotic-assisted surgery.

Telix Pharmaceuticals Boosts Revenue Forecast Amid Strategic Expansions

Telix Pharmaceuticals reported a significant revenue increase of 53% year-over-year for Q3 2025, reaching $206 million, and upgraded its FY 2025 revenue guidance to $800-820 million. The company achieved full reimbursement for Gozellix in the U.S. and expanded its Illuccix product approval to 19 European markets. These developments, along with ongoing clinical trials and strategic market launches, position Telix strongly in the precision medicine sector, enhancing its competitive edge and operational capabilities.

Telix Pharmaceuticals Announces Cessation of Securities

Telix Pharmaceuticals Limited announced the cessation of certain securities, including share rights and share appreciation rights, due to unmet conditions. This development may impact the company’s capital structure and could have implications for its stakeholders, as it reflects adjustments in the company’s financial and operational strategies.

Telix Pharmaceuticals Issues New Securities to Bolster Strategic Growth

Telix Pharmaceuticals Limited announced the issuance of 80,000 ordinary fully paid securities, effective September 11, 2025. This move reflects the company’s ongoing efforts to enhance its financial structure and support its strategic initiatives, potentially impacting its market positioning and offering new opportunities for stakeholders.

Telix Pharmaceuticals Expands ASX Quotation with New Securities

Telix Pharmaceuticals Limited has announced the quotation of new securities on the Australian Securities Exchange (ASX), with a total of 21,815 ordinary fully paid shares being issued. This move is part of the company’s strategic efforts to enhance its capital structure and potentially improve its market position, which could have implications for its stakeholders by increasing the liquidity and visibility of its shares.

Telix Pharmaceuticals Secures Key Reimbursement Status for Gozellix

Telix Pharmaceuticals announced that the U.S. Centers for Medicare & Medicaid Services has granted Transitional Pass-Through payment status for Gozellix, their next-generation PSMA-PET imaging agent for prostate cancer. This designation allows for separate reimbursement under the Hospital Outpatient Prospective Payment System, effective October 1, 2025, and is a key milestone in Telix’s U.S. commercial strategy. Gozellix offers a longer shelf life and extended distribution radius, improving access and efficiency in prostate cancer imaging. The reimbursement status is expected to reduce patient costs and enhance access to advanced imaging, strengthening Telix’s market position as a leader in PSMA-PET/CT imaging.

Challenger Limited Ceases Substantial Holding in Telix Pharmaceuticals

Challenger Limited has announced that it has ceased to be a substantial holder in Telix Pharmaceuticals Ltd. This change in holding status was officially communicated to the ASX, indicating a shift in Challenger’s investment strategy or portfolio composition regarding Telix Pharmaceuticals. The announcement may impact stakeholders by altering the perceived market position or investment appeal of Telix Pharmaceuticals.

Telix Pharmaceuticals and FDA Agree on Resubmission Pathway for TLX101-CDx

Telix Pharmaceuticals has reached an agreement with the U.S. FDA on the resubmission pathway for its New Drug Application for TLX101-CDx, an investigational imaging agent for glioma, a rare brain cancer. The company plans to resubmit the NDA in Q4 2025, following detailed feedback from the FDA, which includes conducting an additional confirmatory efficacy study. The FDA has acknowledged the unmet medical need and indicated that an expedited review is likely, although TLX101-CDx is not included in Telix’s 2025 revenue guidance as it remains an unapproved product.